Thoratec Corp. has agreed to take over the development of Terumo Corp.’s DuraHeart II centrifugal flow ventricular assist device by paying Terumo $13 million up front and up to $43.5 million in future milestone payments based on regulatory approvals and product sales.
Under the deal, announced July 1, Thoratec is licensing intellectual properties and acquiring certain assets related to DuraHeart. It will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?